Prevention of Methylprednisolone Acetate-Induced Osteoporosis with Calcium Administration in Rat Model
-
Iraj Ragerdi Kashani
,
Fatemeh Moradi
,
Parichehr Pasbakhsh
,
Abdollah Sobhani
,
Hosein Nikzad
,
Aligholi Sobhani
Abstract
Glucocorticoid steroids are widely used as anti-inflammatory and immunosuppressive medications and are well known to induce osteoporosis. In Present study 24 rats were randomly divided into four groups (n=6): Group A (control), Group B (sham)that was treated only by normal saline for 1 month.Group C that was treated by methylprednisolone acetate alone (0.2 mg/kg) for 1 month. Group D that was treated by methylprednisolone acetate (0.2 mg/kg) and oral calcium supplementation (15 mg/kg) for 1 month. Changes in concentration of bone metabolic markers such as osteocalcine, acid phosphatase and calcium were evaluated before and after treatment. Bone mineral density (BMD) of lumbar vertebrae was also measured by dual energy X ray absorptiometry (DEXA). The results showed that concentration mean of serum acid phosphatase was increased significantly (P < 0.05) in C and D groups in compared to A and B groups. The concentration mean of serum osteocalcine in group C was decreased significantly (P < 0.05) in comparison to A and B groups but increased significantly in the group D in comparison to group C. The concentration mean of serum calcium was decreased significantly (P < 0.05) in C and D groups in compared to A and B groups. The bone mineral density (g/cm2) was decreased significantly (P < 0.05) in group C in compared to A and B groups. This increased significantly in group D in compared to group C. These results are compatible with the view that low doses of methylprednisolone acetate decreases bone formation and increase bone resorption in the lumbar vertebrae of rats. Calcium administration decreased effects of methylprednisolone.
Aslan M, Simşek G, Yildirim U. Effects of short-term treatment with systemic prednisone on bone healing: anexperimental study in rats. Dent Traumatol 2005; 21(4): 222-5.
Di Munno O, Delle Sedie A. Glucocorticoid-induced osteoporosis and rheumatic diseases. Pathogenesis, prevention and treatment. Reumatismo 2006; 58(1): 11-21.
Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 1998; 27(2): 465-83.
Ishida Y, Heersche JN. Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. J Bone Miner Res 1998; 13(12): 1822-6.
Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. Am J Med 2000; 108(2): 153-64.
Baxter JD. Advances in glucocorticoid therapy. Adv Intern Med 2000; 45: 317-49.
Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994; 4(6): 368-81.
Halioua L, Anderson JJ. Lifetime calcium intake and physical activity habits: independent and combined effects on the radial bone of healthy premenopausal Caucasian women. Am J Clin Nutr 1989; 49(3): 534-41.
Da Silva JA, Jacobs JW, Bijlsma JW. Revisiting the toxicity of low-dose glucocorticoids: risks and fears. Ann N Y Acad Sci 2006; 1069: 275-88.
Bhatt H, Brunet LJ, Stewart CL. Uterine expression of leukemia inhibitory factor coincides with the onset of blastocyst implantation. Proc Natl Acad Sci U S A 1991; 88(24): 11408-12.
Reginster JY. Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities. J Intern Med 2004; 255(6): 615-28.
Villareal MS, Klaustermeyer WB, Hahn TJ, Gordon EH. Osteoporosis in steroid-dependent asthma. Ann Allergy Asthma Immunol 1996; 76(4): 369-72.
Fujita T, Satomura A, Hidaka M, Ohsawa I, Endo M, Ohi H. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy. Calcif Tissue Int 2000; 66(3): 195-9.
Turner RT, Hannon KS, Greene VS, Bell NH. Prednisone inhibits formation of cortical bone in sham-operated and ovariectomized female rats. Calcif Tissue Int 1995; 56(4): 311-5.
King CS, Weir EC, Gundberg CW, Fox J, Insogna KL. Effects of continuous glucocorticoid infusion on bone metabolism in the rat. Calcif Tissue Int 1996; 59(3): 184-91.
Okazaki Y, Tsurukami H, Nishida S, Okimoto N, Aota S, Takeda S, et al. Prednisolone prevents decreases in trabecular bone mass and strength by reducing bone resorption and bone formation defect in adjuvant-induced arthritic rats. Bone 1998; 23(4): 353-60.
Ragerdi-Kashani I, Sobhani A, Moradi F, Pasbakhsh P, Sargolzaei-Avval F. Protective effect of vitamine D3 methylprednisolone acetate (MPA) induced loss of bone metabolism markers and bone mineral density in the lumbar spine of rat. Acta Medica Iranica 2007; 45(1): 1-6.
Gala J, Díaz-Curiel M, de la Piedra C, Calero J. Short- and long-term effects of calcium and exercise on bone mineral density in ovariectomized rats. Br J Nutr 2001; 86(4): 521-7.
Ebbesen EN, Thomsen JS, Beck-Nielsen H, Nepper- Rasmussen HJ, Mosekilde L. Age- and gender-related differences in vertebral bone mass, density, and strength. J Bone Miner Res 1999; 14(8): 1394-403.
Eberhardt AW, Yeager-Jones A, Blair HC. Regional trabecular bone matrix degeneration and osteocyte death in femora of glucocorticoid- treated rabbits. Endocrinology 2001; 142(3): 1333-40.
Fukushima T, Nitta T, Furuichi H, Izumo N, Fukuyama T,Nakamuta H, et al. Bone anabolic effects of PTH(1-34) and salmon calcitonin in ovariectomy- and ovariectomy-steroidinduced osteopenic rats: a histomorphometric and biomechanical study. Jpn J Pharmacol 2000; 82(3): 240-6.
Sobhani A, Moradi F, Pasbakhsh P, Ansari M, Moghadasi M, Ragard-Kashani I. Effects of glucocorticoid on bone metabolism markers and bone mineral density in rats. J Dentistry of Tehran Uni Med Sci 2005; 2(2): 64-9.
King CS, Weir EC, Gundberg CW, Fox J, Insogna KL. Effects of continuous glucocorticoid infusion on bone metabolism in the rat. Calcif Tissue Int 1996; 59(3): 184-91.
Turner RT, Hannon KS, Greene VS, Bell NH. Prednisone inhibits formation of cortical bone in sham-operated and ovariectomized female rats. Calcif Tissue Int 1995; 56(4): 311-5.
Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112(5): 352-64.
Rau R, Wassenberg S, Zeidler H; LDPT-Study Group. Low dose prednisolone therapy (LDPT) retards radiographically detectable destruction in early rheumatoid arthritis--preliminary results of a multicenter, randomized, parallel, double blind study. Z Rheumatol 2000; 59 Suppl 2: II/90-6.
van Everdingen AA, Jacobs JW, Siewertsz Van ReesemaDR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy,disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002; 136(1): 1-12.
Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Inês LB, et al. Safety of low dose glucocorticoid treatmentin rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006; 65(3): 285-93.
Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, aninfusion given once every 3 months, and calcium alone. J Bone Miner Res 2001; 16(1): 104-12.
Devogelaer JP, Goemaere S, Boonen S, Body JJ, KaufmanJM, Reginster JY, et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2006; 17(1): 8-19.
Sambrook PN. Corticosteroid osteoporosis: practical implications of recent trials. J Bone Miner Res 2000; 15(9): 1645-9.
Winters-Stone KM, Snow CM. One year of oral calcium supplementation maintains cortical bone density in young adult female distance runners. Int J Sport Nutr Exerc Metab 2004; 14(1): 7-17.
Krueger D, Checovich M, Gemar D, Wei X, Binkley N. Calcium supplement ingestion may alter lumbar spine bonemineral density measurement. J Clin Densitom 2006; 9(2): 159-63.
Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005; 115(12): 3318-25.
Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for boneloss and fractures and therapeutic implications. Endocr Rev2001; 22(4): 477-501.
Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, et al. Effect ofVitamin D on falls: a meta-analysis. JAMA 2004; 291(16): 1999-2006.
Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002; 966: 73-81.
| Files | ||
| Issue | Vol 47, No 4 (2009) | |
| Section | Original Article(s) | |
| Keywords | ||
| Methylprednisolone acetate osteoporosis bone metabolism markers (BMM) and rat | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
